India Cracks Down on 90% of High-Risk Pharma Plants, Regulator Reports

The Central Drugs Standard Control Organisation (CDSCO) has completed inspections of high-risk manufacturing units across the country, with enforcement actions including product recalls, suspension of manufacturing licenses, and regulatory warnings. The drive, which began in earnest last year, targets facilities producing drugs for both domestic and export markets, following concerns about quality standards.

According to the regulator, the inspections covered a range of facilities identified as high-risk based on past compliance records, product categories, and market reach. Of the plants inspected, about 90% faced some form of regulatory action, though the CDSCO did not specify the exact number of facilities or the breakdown of actions taken.

The crackdown is part of a broader effort to strengthen India's pharmaceutical oversight, particularly after a series of quality failures drew international scrutiny. The regulator has also increased the frequency of surprise inspections and mandated stricter adherence to Good Manufacturing Practices (GMP).

Industry analysts say the move could lead to consolidation in the sector, as smaller manufacturers struggle to meet upgraded standards. The CDSCO has indicated that inspections will continue, with a focus on ensuring that all high-risk plants are brought into compliance or shut down.

The regulator's report did not name specific companies or products, but it emphasized that the actions were aimed at safeguarding public health and maintaining trust in Indian pharmaceuticals, which supply a significant share of generic drugs to global markets.